Claims for Patent: 6,852,705

Summary for Patent: 6,852,705

Title:	DNA vaccines for farm animals, in particular bovines and porcines
Abstract:	Improved vaccines or immunogenic or immunological compositions, and methods for making and using the same.
Inventor(s):	Audonnet; Jean-Christophe Francis (Lyons, FR), Fischer; Laurent Bernard (Sainte Foy les Lyon, FR), Barzu-Le-Roux; Simona (Lentilly, FR)
Assignee:	Merial (Lyons, FR)
Application Number:	09/766,442
Patent Claims:	1. A method for obtaining an immunogenic response comprising administering to a bovine or porcine: (a) a DNA vaccine or immunogenic or immunological composition against a pathogen of a bovine or porcine comprising: (i) a plasmid containing and expressing a nucleotide sequence encoding an immunogen of a pathogen of the bovine or porcine; and (ii) a cationic lipid containing a quaternary ammonium salt, of formula ##STR2## in which R.sub.1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R.sub.2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group; and (b) an inactivated, attenuated live, subunit or recombinant vaccine or immunogenic or immunological composition against a bovine or porcine pathogen, wherein (a) and (b) are administered together in a combination or sequentially. 2. The method according to claim 1 wherein the nucleotide sequence according to (a)(i) comprises a nucleotide sequence of BRSV. 3. The method according to claim 2, wherein the nucleotide sequence of BRSV encodes F antigen and/or G antigen. 4. The method of claim 1 wherein (a) and (b) are sequentially administered, whereby there is a first administration of (b), followed by a subsequent administration of (a). 5. The method of claim 1, wherein the vaccine or immunogenic or immunological composition according to (a) further comprises DOPE. 6. The method of claim 1, wherein the vaccine or immunogenic or immunological composition according to (a) additionally comprises a bovine or porcine GM-CSF protein or an expression vector containing and expressing a nucleotide sequence encoding the GM-CSF protein. 7. The method of claim 1, wherein the cationic lipid is DMRIE. 8. The method of claim 1, wherein the nucleotide sequence encoding the immunogen has deleted therefrom a portion encoding a transmembrane domain. 9. The method of claim 1, wherein the plasmid containing the nucleotide sequence encoding the immunogen further comprises a nucleotide sequence encoding a heterologous signal sequence. 10. The method of claim 9, wherein the heterologous signal sequence is a tPA. 11. The method of claim 1, wherein the plasmid containing the nucleotide sequence encoding the immunogen further comprises a stabilizing intron. 12. The method of claim 11, wherein the stabilizing intron is intron II of rabbit beta-globin gene. 13. The method of claim 1, wherein administration is sequential. 14. The method of claim 13, wherein a prime boost regimen is used. 15. The method of claim 3, wherein the nucleotide sequence of BRSV is optimized by substitution of a heterologous sequence for the signal sequence of the F antigen and/or G antigen of BRSV. 16. The method of claim 15, wherein the heterologous signal sequence is from human tPA. 17. The method of claim 3, herein the nucleotide sequence of BRSV is optimized by deletion therefrom of a portion encoding a transmembrane domain of F antigen and/or G antigen. 18. The method of claim 3, wherein the cationic lipid is DMRIE. 19. The method of claim 18, wherein the vaccine or immunogenic or immunological composition of (a) further comprises DOPE. 20. The method of claim 3, wherein the nucleotide sequence of BRSV encodes F antigen, and wherein the nucleotide sequence is optimized by: (a) insertion of human tPA signal sequence in place of F antigen signal sequence; and (b) deletion of the transmembrane domain and contiguous C-terminal portion. 21. The method of claim 20, wherein the vaccine or immunogenic or immunological composition of (a) further comprises a second expression plasmid comprising a nucleotide sequence encoding BRSV G antigen, and wherein the nucleotide sequence encoding BRSV G antigen is optimized by: (a) insertion of human tPA signal sequence in place of G antigen signal sequence; and (b) deletion of the transmembrane domain and contiguous C-terminal portion. 22. The method of claim 3, wherein administration is sequential. 23. The method of claim 22, wherein a prime boost regimen is used. 24. The method of claim 1, wherein the pathogen of a bovine or porcine in (a) and (b) are the same pathogen. 25. The method of claim 1 wherein (a) and (b) are administered together in a combination. 26. The method of claim 3, wherein (a) and (b) are administered together in a combination.

Details for Patent 6,852,705

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-01-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-01-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-01-21